Compare Lumen Technologies Inc (LUMN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Tango Therapeutics Inc. — how do they compare? Lumen Technologies Inc trades at $4.49 (market cap $5.14B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Lumen Technologies Inc is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Tango Therapeutics Inc. for 0 Days on average.
| LUMN | TNGX | |
|---|---|---|
Market Cap | $5.14B | $3.75B |
Volume | 15,538,010 | 9,619,106 |
Sector | Media | Health |
52-Week High | $11.83 | $32.90 |
52-Week Low | $4.55 | $7.50 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $16.76B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN stock trades at $4.55, down 9.9% in the past 24 hours, reflecting bearish technical signals and negative investor sentiment. The company reported mixed quarterly earnings, with a Q1 2026 miss but a Q2 2026 beat, while full-year 2025 revenue declined to $12.40B with a net loss of $1.74B. High debt levels and a negative ROE of -78.94% highlight financial strain, though recent strategic moves include a Nasdaq listing and new AI-focused networking services to drive growth.
The outlook remains challenging due to persistent losses and heavy debt, but deep value metrics like a low P/S of 0.42 and strategic pivots to AI connectivity offer speculative upside. Key risks include execution on growth initiatives, competitive pressures, and interest rate sensitivity. Analysts are largely cautious, with a 'Reduce' consensus, suggesting limited near-term catalysts.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
